Neuromyelitis optica spectrum disorder+1
Not yet recruitingTwo dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab
Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab
- Disease:Neuromyelitis optica spectrum disorderMultiple sclerosis
- Substances:OcrelizumabRituximab+1
France- Participants:18–64 years
- Substances:Ocrelizumab
- Sponsor:Centre Hospitalier Universitaire De Toulouse





